在SARS-CoV-2感染和COVID-19疫苗接种后的血液凝固和血栓性疾病
Metodija Sekulovski1,2, Niya Mileva3, Georgi Vasilev Vasilev2,4
1Department of Anesthesiology and Intensive Care, University Hospital Lozenetz, Kozyak Str., 1407 Sofia, Bulgaria.
Biomedicines
|October 28, 2023
概括
对于高风险人群来说,COVID-19疫苗是安全的,包括那些患有血栓或出血障碍的人群. 接种疫苗的好处远远超过了罕见的凝血相关不良事件的最小风险.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
背景情况:
- 对于高风险群体的COVID-19疫苗接种安全性仍然存在担忧,特别是那些患有血栓或出血倾向的人.
- 对疫苗接种后的血栓事件的恐惧有助于敏感人群的疫苗犹.
研究的目的:
- 在COVID-19疫苗接种的背景下,审查遗传和获得的血栓/凝血疾病.
- 探索免疫和凝血系统之间的潜在病理生理相互作用.
- 评估有关COVID-19疫苗流血和血栓事件的当前安全数据.
主要方法:
- 关于COVID-19疫苗和凝血障碍的现有文献的叙述性审查.
- 对将疫苗接种与血栓/出血事件联系起来的病理生理机制的分析.
- 讨论有关并发症的诊断成像和治疗干预措施.
主要成果:
- 现有的安全数据表明,COVID-19疫苗和罕见的出血或血栓事件之间没有明确的因果关系.
- 遗传和获得的凝血和血栓性疾病与疫苗的使用有关.
- 讨论了致病的潜在假设,治疗策略和诊断成像.
结论:
- COVID-19疫苗的整体安全概况是有利的,即使在高风险人群中也是如此.
- 预防严重的COVID-19疫苗接种的好处超过了罕见的不良凝血事件的最小风险.
- 持续警和研究对于了解罕见的疫苗相关血栓事件至关重要.
相关概念视频
Disorders of Hemostasis
963
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
963
Anticoagulant Drugs: Low-Molecular-Weight Heparins
723
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
723
Extrinsic and Intrinsic Pathways of Hemostasis
8.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.0K
Blood Transfusion and Agglutination
10.8K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.8K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Coagulation
6.9K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.9K


